WASHINGTON, D.C. - A Florida federal judge did not abuse his discretion in finding that Apotex Inc. and Apotex Corp. (Apotex, collectively) acted inequitably while prosecuting a patent covering the hypertension drug moexipril, the Federal Circuit U.S. Court of Appeals ruled Aug. 15 (Apotex Inc., et al. v. UCB Inc., et al., No. 13-1674, Fed. Cir.).